Phaseline

Companies › OncoResponse

OncoResponse: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OR502
anti-LILRB2 monoclonal antibody
LILRB2Phase 1CancerFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06090266OR502Phase 1CancerOncologyFeb 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

LILRB2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.